Small and mid-size pharmaceutical companies are becoming key innovators in the biotech industry, offering agility and specialized focus. These companies face challenges such as complex clinical trial requirements and regulatory…
The FDA undergoes significant restructuring, impacting thousands of jobs, including the pivotal exit of Peter Marks. Peter Marks, former head of the CBER, was instrumental in advancing cell and gene…
Isomorphic Labs, a spin-off from Alphabet's DeepMind, is revolutionizing AI-powered drug discovery with $600 million in funding from Thrive Capital and Alphabet. Under Demis Hassabis's leadership, the company leverages AI…
The biotech industry is leading healthcare innovation with transformative therapies for complex diseases. Xenon Pharmaceuticals is close to approval for a new epilepsy treatment in Phase 3 trials. Karuna Therapeutics'…
Expedition Therapeutics aims to bring innovative Chinese therapies to the Western medical landscape, focusing on immune and inflammatory diseases. The startup specializes in pioneering bispecific antibody therapies, offering potential breakthroughs…
The partnership between Emergent BioSolutions and Rocketvax drives innovation in global health, focusing on vaccine development for infectious diseases, cancer, and autoimmune disorders. Rocketvax's live-attenuated nasal spray SARS-CoV-2 vaccine exhibits…
Immunai integrates AI with immunology to transform medical innovation. Mikael Dolsten, former Pfizer CSO, joins Immunai's Board, bringing expertise in drug development and past successes like the mRNA COVID-19 vaccine.…
Wisconsin is emerging as a hotspot for biotechnology, driven by both established companies and new ventures. Epic Systems in Verona leads in healthcare technology, creating networks that connect patients and…
Aardvark Therapeutics launches its IPO, marking the first life science IPO of 2025 in San Diego, with its stock starting at $16 on Nasdaq. The company focuses on small molecule…
Brensocatib, developed by Insmed Inc., is anticipated to revolutionize respiratory care for bronchiectasis patients. The drug has received FDA Priority Review, with a potential market launch in the third quarter…